The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20191031: Roper Technologies, Inc.; The Foundry Topco No. 2 Limited
20191084: Genstar Capital Partners VI, L.P.; Joseph M. Brodner
20191085: Genstar Capital Partners VI, L.P.; John R. Brodner and Leslie C. Brodner
Fresenius Medical Care and NxStage Medical, In the Matter of
The FTC required healthcare companies Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to divest all rights and assets related to NxStage’s bloodline tubing set business to B. Braun Medical, Inc. as part of a settlement resolving charges that Fresenius’s proposed $2 billion acquisition of NxStage likely would be anticompetitive. The FTC’s complaint alleges that the proposed merger would harm competition in the U.S. market for bloodline tubing sets that are compatible with hemodialysis machines used in clinics that treat chronic renal failure. Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments. Fresenius and NxStage are two of only three significant suppliers of bloodline tubing sets used in open architecture hemodialysis machines in the United States. Fresenius and NxStage together control 82 percent of the market for bloodlines.The settlement requires Fresenius and NxStage to divest to B. Braun all assets and rights to research, develop, manufacture, market, and sell NxStage’s bloodline tubing sets.